Syros Pharmaceuticals Stock Price Rises Above 50-Day Average

The biotech company's shares trade higher as it advances its lead cancer drug candidate.

Mar. 19, 2026 at 2:20am

Got story updates? Submit your updates here. ›

Shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) rose above their 50-day moving average on Monday, trading as high as $0.0008 per share. The clinical-stage biopharmaceutical company, headquartered in Cambridge, Massachusetts, is developing targeted therapeutics that aim to control gene expression in cancer and rare genetic disorders.

Why it matters

Crossing above the 50-day moving average is often seen as a bullish technical indicator, suggesting the stock may be gaining momentum. For Syros, this comes as the company advances its lead drug candidate, tamibarotene, in clinical trials for acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

The details

Syros Pharmaceuticals is a spin-out from the Broad Institute, leveraging its proprietary gene control platform to identify and develop targeted therapies for previously undruggable gene targets. The company's shares last traded at $0.0002 on Monday, with a trading volume of 6,934 shares. Syros has a market capitalization of $5,366.40 and a beta of 1.31.

  • Syros Pharmaceuticals' stock crossed above its 50-day moving average on Monday, March 19, 2026.

The players

Syros Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, that is pioneering a new class of targeted therapeutics by focusing on the control of gene expression.

Got photos? Submit your photos here. ›

The takeaway

Syros Pharmaceuticals' stock price movement above its 50-day average suggests potential momentum for the company as it advances its lead cancer drug candidate through clinical trials, highlighting the promise of its gene control platform approach to developing targeted therapies.